Company news: Celgene

Share this article:
The FDA expanded the indication for Celgene's drug Abraxane Friday when it approved the injection for use as a first-line treatment for advanced non-small cell lung cancer. The FDA first approved Abraxane for treatment of metastatic breast cancer in 2005 among patients for whom combination chemotherapy did not work. Reuters noted that the drug maker is also seeking additional indications, including pancreatic and skin cancers. Reuters said a Barclays analyst projected that Abraxane could have peak annual lung cancer sales of $110 million.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.